Gefarnate

Cat. No.:	HY-B2206				
CAS No.:	51-77-4				
Molecular Formula:	C ₂₇ H ₄₄ O ₂				
Molecular Weight:	400.64				
Target:	Mucin				
Pathway:	Immunology/Inflammation				
Storage:	Pure form	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4960 mL	12.4800 mL	24.9601 mL
		5 mM	0.4992 mL	2.4960 mL	4.9920 mL
		10 mM	0.2496 mL	1.2480 mL	2.4960 mL
	Please refer to the so	lubility information to select the app	propriate solvent.		
livo		one by one: 10% DMSO >> 40% PE(ng/mL (5.19 mM); Clear solution	G300 >> 5% Tween-8	0 >> 45% saline	
		one by one: 10% DMSO >> 90% (20 g/mL (5.19 mM); Suspended solutior		1	
		one by one: 10% DMSO >> 90% cor ng/mL (5.19 mM); Clear solution	m oil		

	BIOLOGICAL ACTIVITY					
Description Gefarnate is a agent used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of gastritis and gastrit and gastritis and gastritis and gastritis and gastrit	nt of					
In Vitro Gefarnate (0.001, 0.01, or 0.1 mg/mL) increases mucin-like glycoprotein secretion in a dose-dependent fashion, but the difference from the control is significant only at the concentration of 0.1 mg/mL. Gefarnate specifically stimulates the mucin-like glycoprotein secretion ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.						

Product Data Sheet



Landanda on Land

REFERENCES

[1]. Nakamura M, et al. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res. 1997 Oct;65(4):569-74.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA